CHUNLI MEDICAL Reports Interim Results with 4.79% Rise in Net Profit Attributable to Shareholders

Stock News

Aug 29

CHUNLI MEDICAL (01858) has announced its interim results for 2026, showing that while revenue declined, profitability improved year-on-year.

For the reporting period, the company generated approximately RMB 417 million in operating revenue, reflecting a decrease of 14.46% from the prior year. However, net profit attributable to shareholders of the parent company reached about RMB 120 million, up 4.79% year-on-year. Basic earnings per share stood at RMB 0.31.

The company attributed the revenue dip primarily to the execution pace of orthopedic centralized procurement policies and temporary market factors both domestically and internationally. In contrast, the profit growth was driven by the stable supply of centralized procurement products during the period, optimization of the product and market mix, and measures to strengthen the competitiveness of its core business operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1177406517"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177406517\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177406517?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-29 01:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177406517","market":"sg","top_or_hot":-1,"title":"CHUNLI MEDICAL Reports Interim Results with 4.79% Rise in Net Profit Attributable to Shareholders","media":"Stock News","content":"<p><b>CHUNLI MEDICAL</b> (01858) has announced its interim results for 2026, showing that while revenue declined, profitability improved year-on-year.<br><br>For the reporting period, the company generated approximately RMB 417 million in operating revenue, reflecting a decrease of 14.46% from the prior year. However, net profit attributable to shareholders of the parent company reached about RMB 120 million, up 4.79% year-on-year. Basic earnings per share stood at RMB 0.31.<br><br>The company attributed the revenue dip primarily to the execution pace of orthopedic centralized procurement policies and temporary market factors both domestically and internationally. In contrast, the profit growth was driven by the stable supply of centralized procurement products during the period, optimization of the product and market mix, and measures to strengthen the competitiveness of its core business operations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHUNLI MEDICAL Reports Interim Results with 4.79% Rise in Net Profit Attributable to Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHUNLI MEDICAL Reports Interim Results with 4.79% Rise in Net Profit Attributable to Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-29 01:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CHUNLI MEDICAL</b> (01858) has announced its interim results for 2026, showing that while revenue declined, profitability improved year-on-year.<br><br>For the reporting period, the company generated approximately RMB 417 million in operating revenue, reflecting a decrease of 14.46% from the prior year. However, net profit attributable to shareholders of the parent company reached about RMB 120 million, up 4.79% year-on-year. Basic earnings per share stood at RMB 0.31.<br><br>The company attributed the revenue dip primarily to the execution pace of orthopedic centralized procurement policies and temporary market factors both domestically and internationally. In contrast, the profit growth was driven by the stable supply of centralized procurement products during the period, optimization of the product and market mix, and measures to strengthen the competitiveness of its core business operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01858","symbol_name":"春立医疗","start_time":0,"source_url":"","article_id":"1177406517","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177406517","pubTimestamp":1787936686,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CHUNLI MEDICAL (01858) has announced its interim results for 2026, showing that while revenue declined, profitability improved year-on-year.For the reporting period, the company generated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688236":"春立医疗","01858":"春立医疗","BK1100":"医疗保健设备","BK1585":"昨日强势股","BK0251":"专用设备"},"translate_title":"春丽医疗公布中期业绩，股东应占净利润增长4.79%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688236":1,"01858":1},"content_text":"CHUNLI MEDICAL (01858) has announced its interim results for 2026, showing that while revenue declined, profitability improved year-on-year.For the reporting period, the company generated approximately RMB 417 million in operating revenue, reflecting a decrease of 14.46% from the prior year. However, net profit attributable to shareholders of the parent company reached about RMB 120 million, up 4.79% year-on-year. Basic earnings per share stood at RMB 0.31.The company attributed the revenue dip primarily to the execution pace of orthopedic centralized procurement policies and temporary market factors both domestically and internationally. In contrast, the profit growth was driven by the stable supply of centralized procurement products during the period, optimization of the product and market mix, and measures to strengthen the competitiveness of its core business operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}